Join
Live feed
·
PRReleasevia Quantisnow
Cybin Inc. logo

Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule

ByQuantisnow·Wall Street's wire, on your screen.
HELP· Cybin Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track HELP (Cybin Inc.) and more on Quantisnow.